Global Market Presence and Approval: Roxadustat (Evrenzo/Encorete/Rozrex), a first-in-class oral HIF-PHI for anemia of chronic kidney disease, has secured regulatory approvals and is commercialized in numerous countries outside the United States, establishing a significant global market footprint and revenue stream through established partnerships.

Robust Strategic Partnerships: FibroGen benefits from strong collaborations with pharmaceutical giants like AstraZeneca and Astellas, which provide extensive resources for the clinical development, regulatory navigation, and worldwide commercialization of roxadustat, spreading risk and leveraging broad market access.

Diverse and Differentiated Pipeline: The company possesses a promising late-stage pipeline, most notably pamrevlumab, an anti-CTGF antibody, which targets multiple high-value, unmet medical needs such as Idiopathic Pulmonary Fibrosis (IPF), Duchenne Muscular Dystrophy (DMD), and pancreatic cancer, offering significant future growth potential beyond their current marketed product.